Evidence map›Paper›PMID 31877415›Full record

ArticleEBioMedicine2020

Lipidomic profiling identifies signatures of metabolic risk.

Xiaoyan Yin, Christine M Willinger, Joshua Keefe, Jun Liu, Antonio Fernández-Ortiz, Borja Ibáñez, José Peñalvo, Aram Adourian, George Chen, Dolores Corella and 10 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in EBioMedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01410318 (Early Detection and Progression of Subclinical Atherosclerosis and Its Relationship to Coronary Risk Factors), which is not on this map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01410318 active not recruitingnot on this map

Early Detection and Progression of Subclinical Atherosclerosis and Its Relationship to Coronary Risk Factors

TypeobservationalSponsorFundación Centro Nacional de Investigaciones Cardiovasculares Carlos IIIRan2010 to 2030Enrolled4,184ConditionsAtherosclerosis
3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 87 citations in OpenAlex.

  1. Trial
  2. Article
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Lipidomic signatures in Colombian adults with metabolic syndrome.Journal of diabetes and metabolic disorders · 2024
    Article
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 9 institutions in 4 countries.

Xiaoyan YinFramingham Heart Study, Framingham, MA, United States; Department of Mathematics and School of Public Health, Boston University, Boston, MA, United States.
Christine M WillingerFramingham Heart Study, Framingham, MA, United States; Population Sciences Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, United States.
Joshua KeefeFramingham Heart Study, Framingham, MA, United States; Population Sciences Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, United States.
Jun LiuDepartment of Epidemiology, Erasmus Medical Centre, University Medical Center Rotterdam, Rotterdam, Netherlands; Nuffield Department of Population Health, Oxford University, Oxford, UK.
Antonio Fernández-OrtizTufts University, Friedman School of Nutrition Science and Policy, Boston, MA, United States; Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; Department of Cardiology, Hospital Clinico San Carlos, Madrid, Spain; CIBERCV, Madrid, Spain.
Borja IbáñezTufts University, Friedman School of Nutrition Science and Policy, Boston, MA, United States; Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; CIBERCV, Madrid, Spain; Department of Cardiology, IIS-Fundación Jiménez Díaz, Madrid Spain.
José PeñalvoTufts University, Friedman School of Nutrition Science and Policy, Boston, MA, United States.
Aram AdourianBG Medicine, Inc., Waltham, MA, United States.
George ChenFramingham Heart Study, Framingham, MA, United States; Population Sciences Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, United States.
Dolores CorellaDepartment of Preventive Medicine and Public Health, Genetic and Molecular Epidemiology Unit, School of Medicine, University of Valencia, Blasco Ibañez, 15, 46010, Valencia, Spain; CIBER Obesity and Nutrition, Madrid, Spain.
Reinald PamplonaDepartment of Experimental Medicine, University of Lleida-Lleida Biomedical Research Institute (UdL-IRBLleida), Lleida, Spain.
Manuel Portero-OtinDepartment of Experimental Medicine, University of Lleida-Lleida Biomedical Research Institute (UdL-IRBLleida), Lleida, Spain.
Mariona JoveDepartment of Experimental Medicine, University of Lleida-Lleida Biomedical Research Institute (UdL-IRBLleida), Lleida, Spain.
Paul CourchesneFramingham Heart Study, Framingham, MA, United States; Population Sciences Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, United States.
Cornelia M van DuijnDepartment of Epidemiology, Erasmus Medical Centre, University Medical Center Rotterdam, Rotterdam, Netherlands; Nuffield Department of Population Health, Oxford University, Oxford, UK; Leiden Academic Centre for Drug Research, Leiden University, Leiden, Netherlands.
Valentín FusterTufts University, Friedman School of Nutrition Science and Policy, Boston, MA, United States; Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain; Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicina at Mount Sinai School, New York, USA.
José M OrdovásTufts University, Friedman School of Nutrition Science and Policy, Boston, MA, United States; Jean Mayer USDA-Human Nutrition Research on Aging, Tufts University, Boston, MA, United States.
Ayşe DemirkanDepartment of Epidemiology, Erasmus Medical Centre, University Medical Center Rotterdam, Rotterdam, Netherlands; Department of Genetics, University Medical Center Groningen, Groningen, Netherlands.
Martin G LarsonFramingham Heart Study, Framingham, MA, United States; Department of Biostatistics, Boston University School of Public Health, Boston, MA, United States.
Daniel LevyFramingham Heart Study, Framingham, MA, United States; Population Sciences Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, United States. Electronic address: levyd@nih.gov.
National Institutes of Health · USTufts University · USUniversitat de Lleida · ESBoston University · USBG Medicine (United States) · USErasmus MC · NLLeiden University · NLUniversitat de València · ESUniversity Medical Center Groningen · NL

Funding

THE FRAMINGHAM HEART STUDY-N01HC25195-268025195-268025195N01HC025195 · HC · TRUSTEES OF BOSTON UNIVERSITY · PI WOLF, PHILIP A · 2002 to 2006
–
NHLBI NIH HHS N01 HC025195
6 · The paper itself

Abstract

backgroundMetabolic syndrome (MetS), the clustering of metabolic risk factors, is associated with cardiovascular disease risk. We sought to determine if dysregulation of the lipidome may contribute to metabolic risk factors.

methodsWe measured 154 circulating lipid species in 658 participants from the Framingham Heart Study (FHS) using liquid chromatography-tandem mass spectrometry and tested for associations with obesity, dysglycemia, and dyslipidemia. Independent external validation was sought in three independent cohorts. Follow-up data from the FHS were used to test for lipid metabolites associated with longitudinal changes in metabolic risk factors.

resultsThirty-nine lipids were associated with obesity and eight with dysglycemia in the FHS. Of 32 lipids that were available for replication for obesity and six for dyslipidemia, 28 (88%) replicated for obesity and five (83%) for dysglycemia. Four lipids were associated with longitudinal changes in body mass index and four were associated with changes in fasting blood glucose in the FHS.

conclusionsWe identified and replicated several novel lipid biomarkers of key metabolic traits. The lipid moieties identified in this study are involved in biological pathways of metabolic risk and can be explored for prognostic and therapeutic utility.

Indexed as

BiomarkersLipid MetabolismLipidomicsAdultAgedAnimalsCross-Sectional StudiesDisease SusceptibilityFemaleHumansLipidsLongitudinal StudiesMaleMetabolic SyndromeMiddle AgedRisk AssessmentBiomarkersLipidsBiomarkerCardiovascular diseaseDysglycemiaDyslipidemiaMetabolic riskMetabolic syndrome

Identifiers

PMID31877415
PMCPMC6938899
OpenAlexW2998301974

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.